Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Short-term Investments (2019 - 2025)

IDEAYA Biosciences' Short-term Investments history spans 7 years, with the latest figure at $526.6 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 11.04% year-over-year to $526.6 million; the TTM value through Dec 2025 reached $526.6 million, down 11.04%, while the annual FY2025 figure was $526.6 million, 11.04% down from the prior year.
  • Short-term Investments for Q4 2025 was $526.6 million at IDEAYA Biosciences, down from $591.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $591.9 million in Q4 2024 and bottomed at $154.7 million in Q4 2021.
  • The 5-year median for Short-term Investments is $278.3 million (2022), against an average of $303.7 million.
  • The largest YoY upside for Short-term Investments was 703.41% in 2021 against a maximum downside of 26.86% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $154.7 million in 2021, then skyrocketed by 91.44% to $296.2 million in 2022, then increased by 24.27% to $368.1 million in 2023, then skyrocketed by 60.81% to $591.9 million in 2024, then dropped by 11.04% to $526.6 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Short-term Investments are $526.6 million (Q4 2025), $591.9 million (Q4 2024), and $518.6 million (Q2 2024).